Top

Published in:

01-06-2010 | Letter to the Editor

Sustained lower rates of breast cancer incidence in France in 2007

Authors: Brigitte Séradour, Hubert Allemand, Alain Weill, Philippe Ricordeau

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Excerpt

We previously reported a decrease in breast cancer incidence between 2003 and 2006 for only women aged 50 or above in France [1]. The magnitude and timing of decrease varied by age [2]. This was in the context of a substantial reduction in hormonal replacement therapy (HRT) prescriptions after 2001. …

Allemand H, Séradour B, Weill A, Ricordeau P (2008) Decline in breast cancer incidence in 2005 and 2006 in France : a paradoxical trend. Bull Cancer 95(1):11–15PubMed

Séradour B, Allemand H, Weill A, Ricordeau P (2009) Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer. doi: 10.1684/bdc.2009.0869

Lambe M, Wigertz A, Holmqvist M, Adolfsson J et al (2009) Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. Breast Cancer Res Treat. doi: 10.1007/s10549-009-0615-7

Kumle M (2008) Declining breast cancer incidence and decreased HRT use. Lancet 372:608–610CrossRefPubMed

Cronin KA, Ravdin PM, Edwards BK (2008) Sustained lower rates of breast cancer in the United States. Breast Cancer Res Treat. doi: 10.1007/s10549-008-0226-8

Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9:R28. doi:10.1186/bcr1672 CrossRefPubMed

Canfell K, Banks E, Clements M et al (2009) Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003. Breast Cancer Res Treat. doi: 10.1007/s10549-009-0331-3

Katalanic A, Rawal R (2008) Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107:427–430CrossRef

Bouchardy C, Usel M, Verkooijen HM, Fioretta G et al (2009) Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva. Breast Cancer Res Treat. doi: 10.1007/s10549-009-0478-y

Title: Sustained lower rates of breast cancer incidence in France in 2007
Authors: Brigitte Séradour
Hubert Allemand
Alain Weill
Philippe Ricordeau
Publication date: 01-06-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0779-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2010

Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells

Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years

High levels of uPA and PAI-1 predict a good response to anthracyclines

Tamoxifen sensitivity and estrogen receptor mRNA levels

Density of tumour stroma is correlated to outcome after adoptive transfer of CD4+ and CD8+ T cells in a murine mammary carcinoma model

High levels of uPA and PAI-1 predict a good response to anthracyclines

Keynote webinar | Spotlight on antibody–drug conjugates in cancer